AstraZeneca’s Imfinzi Gets US Approval for Bladder Cancer Treatment 
U.S. Stock Futures Drop on Tariff Fears and Inflation Concerns 
ReliaQuest Secures $500M to Boost AI Cybersecurity, Hits $3.4B Valuation 
BOC Aviation Orders 120 Boeing and Airbus Aircraft to Expand Fleet 
Trump Threatens Tariffs on Russian Oil Buyers Amid Frustration with Putin 
Toyota Hybrid Demand Causes Delays and Supply Chain Issues 
Virgin Australia Prepares for ASX Return Following Profit Surge 
CK Hutchison Shares Rise Ahead of Panama Ports Sale to BlackRock-Led Group 
EU Ready to Hit Back if U.S. Imposes New Trade Tariffs, Says von der Leyen 
US Stock Futures Slip Amid Recession Fears and Trump Tariff Plan 
Russia Stocks Slide as MOEX Hits 1-Month Low 
CK Hutchison Shares Fall Amid China Criticism Over Panama Port Sale to BlackRock 
OpenAI Secures $40B from SoftBank, Reaches $300B Valuation Amid AI Boom 
Celltrion Inc., a biopharmaceutical company headquartered in Incheon, South Korea, is merging with its Celltrion Healthcare subsidiary in an effort to strengthen its business synergy or combined effort. The biosimilar producer and its biosimilar marketing unit are set to be consolidated this year.
Seo Jung Jin, Celltrion Group’s chairman, said on Thursday, Aug. 17, that once Celltrion is incorporated with Celltrion Healthcare, the newly-formed entity will also take in Celltrion Pharma. The chairman said this integration will eventually happen later but did not provide an exact time frame. After all the mergings, Celltrion, Celltrion Healthcare, and the company’s chemical pharma producer will work together as one.
According to The Korea Times, Celltrion revealed its plan to acquire Celltrion Healthcare during the company’s recent regulatory filing. The changes will also entail the issuance of new shares of Celltrion to shareholders of Celltrion Healthcare, and the merger ratio is expected to stand at 1:0.4492620.
It was mentioned that the Celltrion chairman holds a 95% stake in Celltrion Holdings which in turn holds a 20.02% stake in Celltrion. The holdings also have a 35.54% stake in Celltrion Healthcare and a 54.96% stake in Celltrion Pharm.
"Celltrion is expected to complete the merger of Celltrion Healthcare by the end of the year, followed by the next merger with Celltrion Pharm in the next six months," Seo Jung Jin shared during an online conference.
The Celltrion Group said it will merge the mentioned companies, but the plan still needs the approval of shareholders. This may be completed on October 23 at the shareholders' meeting. Celltrion and Celltrion Healthcare will eventually be dissolved after the merger.
To date, while the merger is still being processed, The Korea Herald reported that Celltrion is focusing on producing and developing bio-pharmaceutical products while Celltrion Healthcare is working more on selling these products.
Photo by: Celltrion Press Room
